开发和评估固体脂质纳米颗粒,以提高capecitabine的口服生物可用性
Mayukh Jana1, Chandra Sekhar Patro2, Suraj Sharma3
1School of Pharmacy, Centurion University of Technology and Management, Centurion University, Bhubaneswar, Odisha, India.
Journal of biomaterials science. Polymer edition
|May 16, 2025
概括
这项研究开发了固体脂质纳米颗粒 (SLN) 以提高capecitabine (CPB) 的生物可用性. 开发的CPB-SLNs表现出持续释放和长时间的血保留,这表明抗癌药物递送有所改善.
科学领域:
- 纳米技术 纳米技术
- 药品制造 药品制造 药品制造
- 药理动力学 药理动力学
背景情况:
- 皮他 (CPB) 是一种具有可变生物可用性的口服化疗剂.
- 固体脂质纳米颗粒 (SLN) 为改善药物输送和治疗疗效提供了一个有前途的平台.
研究的目的:
- 开发和描述加载capecitabine的固体脂质纳米粒子 (CPB-SLNs).
- 评估CPB-SLNs的体外和体内性能,以提高口服生物可用性.
主要方法:
- 通过修改的纳米沉方法来制备SLN.
- 特性包括颗粒大小,泽塔潜力,捕获效率,药物负载,体外释放,TEM,体内药物动力学,稳定性,组织病理学和细胞毒性研究.
主要成果:
- SLNs的颗粒大小在13.06到86.10 nm之间.
- F-3配方显示了最高的捕获效率 (45.49%).
- 与原始CPB相比,CPB-SLNs表现出持续的药物释放,延长的血保留,延迟的Tmax和延长的半衰期,在200mg/kg/day时观察到毒性.
结论:
- 开发的CPB-SLNs有效地改善了capecitabine的口服生物可用性和药理动力学特征.
- 这些SLN代表了抗癌药物的有前途的输送系统,可能提高治疗效果.
相关概念视频
Factors Affecting Dissolution: Particle Size and Effective Surface Area
2.0K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
2.0K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
329
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
329
Bioavailability Enhancement: Drug Solubility Enhancement
448
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
448
Bioavailability Enhancement: Drug Permeability Enhancement
308
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
308
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
311
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
311
Modified-Release Drug Delivery Systems: Bioavailability
119
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
119


